The expert panel provides perspective on current therapeutic gaps and key barriers to care.
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Kabiri discusses the large unmet need for decades of having a consistently formulated prescription product that addresses the evaporative dry eye disease (DED) component. This allows for aligned patient and provider perspectives on outcomes. A recently approved product helps address this need.
Haumschild asks about additional gaps a new DED product could address. Kabiri notes other forms of keratitis can arise from DED, interfere with treatment response, and lack a “bridge” product to rein these in. The new product targeting evaporative DED allows other metrics like corneal staining and tear breakup time to demonstrate improvement at predictable time points. This predictability can promote treatment compliance.
Haumschild asks about key patient challenges around DED diagnosis and access to appropriate treatments. Kabiri notes a growing younger patient demographic with more evaporative DED from digital device use. DED with an evaporative component can lead to secondary keratitis, glaucoma, drop tolerance, and related issues. Though immunomodulators help address inflammation, residual evaporative DED may persist. The recent FDA approval targeting evaporative DED and overall DED offers an exciting new option for this major unmet need.
Parekh also cites a newly approved treatment for a subset of blepharitis patients. Additional pipeline innovations offer promise for comprehensively addressing DED’s unmet needs in the future.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
2 Commerce Drive
Cranbury, NJ 08512